World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0009671515
Reproduction Date:

Title: Pentoxyverine  
Author: World Heritage Encyclopedia
Language: English
Subject: ATC code R05, Sigma receptor, Dimemorfan, Dextromethorphan, Antitussives
Collection: Amines, Antitussives, Carboxylate Esters, Ethers
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
2-[2-(diethylamino)ethoxy]ethyl 1-phenylcyclopentanecarboxylate
Clinical data
  • No studies; contraindicated
Legal status
Routes of
Oral, rectal
Pharmacokinetic data
Metabolism Hepatic
Biological half-life 2.3 hours (oral), 3–3.5 hours (rectal)
Excretion Renal
CAS Registry Number  N
23142-01-0 (dihydrogen citrate)
1406-98-0 (tannate)
ATC code R05
PubChem CID:
ChemSpider  Y
Chemical data
Formula C20H31NO3
Molecular mass 333.465 g/mol

Pentoxyverine (rINN) or carbetapentane is an antitussive (cough suppressant) commonly used for cough associated with illnesses like common cold. It is sold over-the-counter in the United States as Solotuss,[1] or in combination with other medications, especially decongestants. One such product is Certuss, a combination of guaifenesin and pentoxyverine.[2]

The drug is available in the form of drops, suspensions and suppositories.[1][3]


  • Uses 1
  • Contraindications 2
  • Adverse effects 3
  • Overdose 4
  • Interactions 5
  • Mechanism of action 6
  • Pharmacokinetics 7
  • Chemical properties 8
  • References 9


The drug is used for the treatment of dry cough associated with conditions such as common cold, bronchitis or sinusitis. Like codeine and other antitussives, it relieves the symptom, but does not heal the illness.[1] No controlled clinical trials regarding the efficiency of pentoyxverine are available.[4]

Pharmacologists use the substance as a selective agonist at the sigma-1 receptor in animal[5] and in vitro experiments.[6][7]


Pentoxyverine is contraindicated in persons with bronchial asthma[4] or other kinds of respiratory insufficiency (breathing difficulties), as well as angle-closure glaucoma. No data are available for the use of pentoxyverine during pregnancy, lactation, or children under two years of age, wherefore the drug must not be used under these circumstances.[3]

Antitussive drugs are not useful in patients with extensive phlegm production because they prevent coughing up the phlegm.[4]

Adverse effects

The most common side effects (seen in more than 1% of patients) are upper abdominal (belly) pain, diarrhoea, dry mouth, and nausea or vomiting. Allergic reactions of the skin like itching, rashes, hives and angiooedema are rare. The same is true for anaphylactic shock and convulsions.[3][8]


Overdosage leads to drowsiness, agitation, nausea and anticholinergic effects like tachycardia (high heart rate), dry mouth, blurred vision, glaucoma, or urinary retention.[1][3] Especially in children, pentoxyverine can cause hypoventilation,[4] but much more seldom than codeine and other opioid antitussives.

The treatment of overdosage aims at the symptoms; there are no specific antidotes available.[3]


No interactions have been described at usual doses. It is possible that pentoxyverine can increase the potency of sedative drugs like benzodiazepines, some anticonvulsants and antidepressants, and alcohol. Likewise, some consumer informations warn patients from taking the drug in combination with or up to two weeks after monoamine oxidase inhibitors, which are known to cause potentially fatal reactions in combination with the (chemically only distantly related) antitussive dextromethorphan.[1][3][4]

Mechanism of action

Pentoxyverine suppresses the cough reflex in the central nervous system,[1] but the exact mechanism of action is not known with certainty. The drug acts as an antagonist at muscarinic receptors[3] (subtype M1) and as an agonist at sigma receptors (subtype σ1).[5] Its anticholinergic properties can theoretically relax the pulmonary alveoli and reduce phlegm production. Spasmolytic and local anaesthetic properties have also been described.[4] The clinical relevance of these mechanisms is uncertain.


The substance is absorbed quickly from the gut and reaches its maximum plasma concentration (Cmax) after about two hours. If applied rectally, Cmax is reached after four hours. The bioavailability of the suppositories, measured as area under the curve (AUC), is about twofold that of oral formulations, due to a first pass effect of over 50%. By far the most important metabolisation reaction is ester hydrolysis, which accounts for 26.3% of the total clearance through the kidneys. Only 0.37% are cleared in form of the original substance.[3] The plasma half life is 2.3 hours for oral formulations and three to 3.5 hours for suppositories.[9] Pentoxyverine is also excreted into the breast milk.[3]

Chemical properties

Pentoxyverine dihydrogen citrate, the salt that is commonly used for oral preparations, is a white to off-white, crystalline powder. It dissolves easily in water or chloroform, but not in benzene, diethyl ether, or petroleum ether, and melts at 90–95 °C.[4] Other orally available salts are the hydrochloride and the tannate;[10] suppositories contain the free base.[3]


  1. ^ a b c d e f "Carbetapentane". 
  2. ^ "Certuss". 
  3. ^ a b c d e f g h i j Jasek, W., ed. (2008). Austria-Codex (in German) (63 ed.). Vienna: Österreichischer Apothekerverlag.  
  4. ^ a b c d e f g Dinnendahl, V.; Fricke, U., eds. (2010). Arzneistoff-Profile (in German) 4 (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag.  
  5. ^ a b Brown, C.; Fezoui, M.; Selig, W. M.; Schwartz, C. E.; Ellis, J. L. (2004). "Antitussive activity of sigma-1 receptor agonists in the guinea-pig". British Journal of Pharmacology 141 (2): 233–240.  
  6. ^ Kume, T.; Nishikawa, H.; Taguchi, R.; Hashino, A.; Katsuki, H.; Kaneko, S.; Minami, M.; Satoh, M.; Akaike, A. (2002). "Antagonism of NMDA receptors by sigma receptor ligands attenuates chemical ischemia-induced neuronal death in vitro". European Journal of Pharmacology 455 (2–3): 91–100.  
  7. ^ "Carbetapentane Citrate CAS#: 23142-01-0". Chemicalbook. 
  8. ^ Dootz, H.; Kuhlmann, A.; Hoffmann, K. (eds.). Rote Liste (in German) (2005 ed.). Aulendorf: Editio Cantor. 24 037.  
  9. ^ Steinhilber, D.; Schubert-Zsilavecz, M.; Roth, H. J. (2005). Medizinische Chemie [Medical Chemistry] (in German). Stuttgart: Deutscher Apothekerverlag. p. 190.  
  10. ^ "Pentoxyverine Full Prescribing Information".  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.